Koji Sakamoto Japan

Dr. Koji Sakamoto is Associate Professor in the Department of Respiratory Medicine at the Graduate School of Medicine, Nagoya University, Japan. He received his M.D. from Nagoya University in 2001 and earned his Ph.D. from the same institution in 2012. After several years of clinical training at Tosei General Hospital, a major referral center for interstitial lung diseases (ILDs) in Japan, he pursued postdoctoral research in pulmonary biology at Yale University. Dr. Sakamoto’s research focuses on the mechanisms underlying lung injury and pulmonary fibrosis, integrating clinical observations with translational investigation. His recent work has particularly focused on elucidating the pathogenesis of pulmonary fibrosis, identifying novel biomarkers, and exploring potential therapeutic targets. He has authored more than 100 peer-reviewed publications and has received several international honors, including the Pulmonary Fibrosis Foundation I.M. Rosenzweig Junior Investigator Award. He also contributes to national guideline development and scientific committees related to diffuse lung diseases.
Job Title
Associate Professor
Faculty / Department / Division
Faculty of Medicine, Department of Pulmonary Medicine
Institution / Organisation
Nagoya University

20 November 2026, Friday

Time Session
08:00
08:30
APSR’s Leadership in Advancing Respiratory Medicine and Sciences in Asia
Yoshinori Hasegawa Speaker Japan
Ahmad Izuanuddin Ismail Chairperson Malaysia
Established in 1986 to advance respiratory medicine and combat respiratory diseases in the Asia-Pacific, the Asian Pacific Society of Respirology (APSR) has grown into a major international society and a Founding Member of the Forum of International Respiratory Societies (FIRS). The APSR’s mission is to advance and disseminate knowledge of the respiratory system in health and disease across the Asia-Pacific and globally, aiming to bridge regional healthcare disparities and elevate research, education, and clinical practice. Guided by its vision to reshape the future of respiratory medicine through innovative, patient-centered, equitable, and sustainable care, the Society promotes collaboration among researchers and clinicians to provide optimal respiratory care tailored to the region’s diverse healthcare infrastructures and disease burdens. This lecture reviews the past year's achievements and key initiatives across five core pillars: hosting the annual APSR Congress, publishing official journals (Respirology and Respirology Case Reports), nurturing early-career researchers through education and fellowships, leading Assembly and Section activities, and advancing global advocacy and international partnerships. A defining feature of the APSR is its "en bloc" society membership system. By integrating national respiratory societies, this strategy driven rapid expansion, rendering the APSR the largest respiratory society in the region. This sheer scale grants the Society strong leverage in international negotiations and policy advocacy alongside global bodies such as the WHO, ATS, and ERS. The en bloc membership system has expanded the APSR's reach and strengthened collaboration among respiratory societies across the Asia-Pacific. Building on this foundation, the APSR aims to encourage greater individual member participation and raise awareness of benefits such as journal access, educational programs, and fellowships. Closer partnerships with national and regional societies, together with clearer communication of the APSR's achievements, will further strengthen members' sense of connection and shared purpose. These efforts will enhance membership value and support the Society's sustainable growth.
Ballroom 3, Lower Ground Floor
08:00
12:00
16:30
18:00

21 November 2026, Saturday

Time Session
11:00
12:30
Nurhayati Mohd Marzuki Chairperson Malaysia
  • Keiji Fujiwara Presenter Japan
  • Tomonori Sato Presenter Japan
  • Toshitaka Shomura Presenter Japan
    【Background and Aims】 Bendopnea, defined as dyspnea while bending forward, has been primarily studied in heart failure, but its significance in chronic obstructive pulmonary disease (COPD) remains unclear. Airway mucus plugging, quantified by computed tomography (CT), has emerged as an important imaging marker linked to airflow limitation and symptom burden in COPD. We hypothesized that a higher CT-based mucus plug score is independently associated with the presence of bendopnea in COPD patients. 【Methods】 We conducted a retrospective cross-sectional study of 133 patients with COPD. Bendopnea was assessed clinically and was present in 27 patients (20.3%). Mucus plug score was quantified from chest CT images. Patient demographics, pulmonary function tests, low attenuation volume percentage (LAV%), hemodynamic parameters (BNP, TRPG, EF), and symptom scores were compared between groups. Multivariate logistic regression analyses were performed to evaluate the independent association of mucus plug score with bendopnea, adjusting for %FEV1 and LAV%. 【Results】 Bendopnea-positive group exhibited significantly higher mucus plug scores compared to the Bendopnea-negative group (median 2.0 [IQR 1.0–4.0] vs. 0.0 [0.0–1.0], p < 0.001). The Bendopnea-positive group also demonstrated more severe airflow limitation (%FEV1: 51.3% vs. 73.7%, p < 0.001), greater emphysema (LAV%: 12.2% vs. 3.6%, p = 0.008). In contrast, hemodynamic parameters showed no significant between-group differences. In multivariate logistic regression analyses, mucus plug score remained a significant independent predictor of bendopnea across all models: adjusted for %FEV1, adjusted for LAV%, adjusted for both %FEV1 and LAV%. Bendopnea prevalence increased with rising mucus plug scores (P for trend < 0.001). 【Conclusions】 CT-based mucus plug score is significantly and independently associated with bendopnea in COPD patients, irrespective of the degree of airflow limitation, emphysema. These findings suggest that bendopnea may be a clinical clue to mucus-predominant airway disease in COPD.
  • Shih-Yu Chen Presenter Taiwan
    Background The prognostic value of body mass index (BMI) in chronic obstructive pulmonary disease (COPD) remains inconsistent. The clinical implications of phenotyping based on adiposity and muscularity have not been well established. Methods In this prospective multicenter cohort study, patients with spirometry-confirmed COPD (October 2021–December 2023) underwent bioelectrical impedance analysis. Low fat-free mass index (FFMI) was defined as <17.4 kg/m² (men) and <15.0 kg/m² (women); high fat mass index (FMI) as ≥5.9 kg/m² (men) and ≥7.0 kg/m² (women). Participants were classified into four phenotypes: lean-robust (low FMI, high FFMI), wasting (low FMI, low FFMI), sarcopenic obesity (high FMI, low FFMI), and obese-robust (high FMI, high FFMI). The primary outcome was severe acute exacerbation; the secondary outcome was three-year all-cause mortality. Cox proportional hazards models were applied. Results Among 648 participants (mean age 73.2 years; 88.6% male), 6.9% were underweight, 29.9% overweight and 4.9% obese by BMI. Compared with normal weight, underweight was associated with higher risk of severe exacerbation (HR 2.05, 95% CI: 1.27–3.32) and mortality (HR 2.94, 95% CI: 1.50–5.77), whereas overweight showed lower mortality risk (HR 0.24, 95% CI 0.09–0.61). Based on adiposity–muscularity phenotyping, 21.9% were lean-robust, 28.4% wasting, 20.1% sarcopenic obesity, and 29.6% obese-robust. Using lean-robust as reference, wasting and sarcopenic obesity were associated with increased risks of severe exacerbation (HR 1.96, 95% CI:1.26-3.06; HR 1.81, 95% CI:1.12-2.94) and mortality (HR 12.6, 95% CI: 3.01-53.2; HR 15.2, 95% CI: 3.57-64.61). The obese-robust demonstrated comparable risks of severe exacerbation and mortality to the lean-robust group. Conclusion BMI alone inadequately stratifies prognosis in COPD. Phenotyping based on adiposity and muscularity identifies high-risk subgroups more precisely. The apparent obesity paradox may reflect preserved muscularity rather than adiposity itself, underscoring the importance of body composition assessment in clinical practice.
  • Ming Yang Presenter Hong Kong
    Background: Paediatric obstructive sleep apnoea (OSA) is a prevalent disorder characterised by recurrent upper airway obstruction, resulting in hypoxia and sleep fragmentation. Epidemiological evidence links Interleukin (IL)-17A to OSA. However, few studies have examined both local and systemic IL 17A profiles to identify meaningful inflammatory phenotypes, and the relationship between these phenotypes and polysomnographic indices remains unclear. Methods: Children aged 5-12 years underwent clinical assessment and polysomnography. Plasma and nasal epithelial lining fluid (NELF) IL-17A were measured by cytometric bead array, with K-means clustering of standardised values identifying inflammatory phenotypes. Across clusters, differences in obstructive apnoea-hypopnoea index (OAHI), oxygen desaturation index (ODI), and arousal index (ARI) were evaluated using Kruskal-Wallis tests with Dunn's post-hoc tests and confounder-adjusted generalised linear models (GLMs). Results: One hundred and six children were recruited, with plasma and NELF collected. Three distinct IL-17A inflammatory phenotypes were identified as high-IL-17A (n=59), low-IL-17A (n=22), and discordant-IL-17A profiles (n=25) (Figure 1). OAHI (p=0.014) and ARI (p=0.002) differed significantly across clusters, whereas ODI (p=0.837) showed no significant differences. Post-hoc test showed significantly higher OAHI (median (Q1-Q3): 3.23 (0.60-17.12) vs. 0.63 (0.22-2.06), adjusted p=0.022) and ARI (13.70 (9.21-25.63) vs. 8.79 (7.15-10.76), adjusted p=0.003) in the high-IL-17A cluster than those in the low-IL-17A cluster. GLMs showed that both low IL 17A and discordant-IL-17A clusters had significantly lower OAHI than the high IL 17A cluster (low: β=-0.692, 95%CI(-1.280,-0.105), p=0.023; discordant: β=-0.664, 95%CI(-1.223,-0.104), p=0.022), with the same pattern for ARI (low: β=-0.338, 95%CI(-0.604,-0.071), p=0.015; discordant: β=-0.294, 95%CI(-0.548,-0.041), p=0.025), while no significant differences for ODI. Conclusions: Clustering IL-17A from plasma and NELF revealed a distinct inflammatory phenotype with more respiratory events and fragmented sleep. These findings support IL-17A as a biomarker for identifying children with a distinct pattern of specific OSA-related features.
  • Scott J. Denstaedt Presenter United States
  • Rachel Kohn Presenter United States
Function Room 8, Ground Mezzanine Floor
14:00
15:30
Hsing-Chen Tsai Chairperson Taiwan
Wong Jyi Lin Chairperson Malaysia
  • Arata Azuma Speaker Japan
    “Latest Treatments for Pulmonary Fibrosis: Pharmacological Effects and Therapeutic Outcomes” Arata Azuma , Japan Abstract: This article provides an overview of the development of treatments for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). As existing therapies—such as pirfenidone and nintedanib—do not always yield sufficient efficacy, the development of nerandomilast was pursued with the expectation of providing additional therapeutic benefit. Findings suggest that this approach may not only inhibit the decline in forced vital capacity (FVC) but also extend patient survival. Meanwhile, research into TAS-115 failed to demonstrate the intended therapeutic effect. Currently, investigations targeting LPA1 and PDE5 inhibition are also underway. Efforts to develop therapeutic agents with distinct mechanisms of action continue, with careful evaluation of whether their adverse event profiles remain within an acceptable range compared to existing treatments. The ultimate goal is to halt the deterioration of respiratory function and improve patient survival.
  • Namkoong Ho Speaker Japan
    "Understanding host genetic susceptibility is crucial for unraveling the pathogenesis of infectious pulmonary diseases and developing personalized clinical strategies. In the first part of this presentation, we focus on severe COVID-19. Through a genome-wide association study (GWAS) in a Japanese cohort, we identified a risk variant at 5q35 (rs60200309-A) near DOCK2, which is associated with severe COVID-19 in patients under 65 years of age. Single-cell RNA sequencing and functional analyses revealed cell-type-specific downregulation of DOCK2 in non-classical monocytes, leading to impaired macrophage recruitment and dysregulated type I interferon responses. Importantly, this risk allele is prevalent in East Asians but rare in Europeans, underscoring the critical need for genetic studies in non-European populations(Namkoong, et al. Nature 2022.). In the second part, we transition to nontuberculous mycobacterial pulmonary disease (NTM-PD). By expanding our genomic investigation to multinational cohorts across Korea, Japan, and Europe, we identified and validated three susceptibility loci (IL1Rs, PDE8B, and PRKCB). Furthermore, Mendelian randomization analysis demonstrated a significant negative causal relationship between body mass index (BMI) and NTM-PD susceptibility(Park, et al. Am J Respir Crit Care Med . 2025). Together, these findings highlight that establishing multinational and multi-ethnic cohorts is indispensable for precision respirology, as it allows us to uncover both population-specific risk variants and globally conserved host mechanisms in respiratory infections."
  • Koji Sakamoto Speaker Japan
    Acute lung injury (ALI), including acute respiratory distress syndrome (ARDS), is a life-threatening syndrome triggered by systemic insults such as infection or trauma. It is characterized by intense pulmonary inflammation and increased vascular permeability that disrupt gas exchange. Despite decades of investigation, therapeutic strategies targeting aberrantly activated inflammatory cells, including corticosteroids, have produced inconsistent clinical benefits, underscoring the need for new mechanistic insights and therapeutic targets. Recent advances in innate immunology have begun to reveal pathways that regulate the dysregulated activation of phagocytes such as neutrophils and macrophages, highlighting previously unrecognized drivers of inflammatory tissue injury. In this lecture, I will discuss emerging mechanisms that amplify lung inflammation, with particular emphasis on inflammatory feedback loops between neutrophils and macrophages and on DNA-triggered inflammatory signaling pathways as potential drivers of organ injury, integrating insights from our recent studies.
  • Q&A
Ballroom 1, Lower Ground Floor